1887

Abstract

The objective of this study was to evaluate the effect of heparin binding to cells on their survival in the presence of fresh rabbit serum with or without active complement components. Three strains were compared and the amounts of heparin added reflected the physiological concentrations that can be found in animal tissues. No growth of was noted in the presence of serum. Serum with or without active complement produced a reduction in c.f.u. for strains SPM 326, CCUG 17874 and SS1. However, addition of heparin resulted in increased survival of bacterial cells in serum with or without active complement. It appears that heparin binding to can prevent bacterial cell death due to the alternative complement system. Heparin binding could also protect from heated serum (complement-inactivated), indicating protection from other serum components besides complement. , the process of heparin binding could possibly result in facilitated colonization due to a higher survival rate.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.05389-0
2004-01-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/53/1/JM530102.html?itemId=/content/journal/jmm/10.1099/jmm.0.05389-0&mimeType=html&fmt=ahah

References

  1. Ascensio F., Hansson H. A., Larm O., Wadstrom T. 1995; Helicobacter pylori interacts with heparin and heparin-dependent growth factors. FEMS Immunol Med Microbiol 12:265–272 [CrossRef]
    [Google Scholar]
  2. Blom A. M. 2002; Structural and functional studies of complement inhibitor C4b-binding protein. Biochem Soc Trans 30:978–982
    [Google Scholar]
  3. Chmiela M., Czkwianianc E., Wadstrom T., Rudnicka W. 1997; Role of Helicobacter pylori surface structures in bacterial interaction with macrophages. Gut 40:20–24 [CrossRef]
    [Google Scholar]
  4. Dubreuil J. D., Del Giudice G., Rappuoli R. 2002; Helicobacter pylori interactions with host serum and extracellular matrix proteins: potential role in the infectious process. Microbiol Mol Biol Rev 66:617–629 [CrossRef]
    [Google Scholar]
  5. Duensing T. D., Wing J. S., van Putten J. P. M. 1999; Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis. Infect Immun 67:4463–4468
    [Google Scholar]
  6. Gonzales-Valencia G., Perez-Perez G. I., Washburn R. G., Blaser M. J. 1996; Susceptibility of Helicobacter pylori to the bactericidal activity of human serum. Helicobacter 1:28–33 [CrossRef]
    [Google Scholar]
  7. Lee A., O'Rourke J., Corazon De Ungria M., Robertson B., Daskalopoulos G., Dixon M. F. 1997; A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 112:1386–1397 [CrossRef]
    [Google Scholar]
  8. Lovich M. A., Edelman E. R. 1999; Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo . Proc Natl Acad Sci U S A 96:11111–11116 [CrossRef]
    [Google Scholar]
  9. Marchetti M., Arico B., Burroni D., Figura N., Rappuoli R., Ghiara P. 1995; Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 267:1655–1658 [CrossRef]
    [Google Scholar]
  10. Montemurro P., Nishioka H., Dundon W. G., de Bernard M., Del Giudice G., Rappuoli R., Montecucco C. 2002; The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a potent stimulant of mast cells. Eur J Immunol 32:671–676 [CrossRef]
    [Google Scholar]
  11. Ngeleka M., Harel J., Jacques M., Fairbrother J. M. 1992; Characterization of a polysaccharide capsular antigen of septicemic Escherichia coli O115 : K`‘V165’' : F165 and evaluation of its role in pathogenicity. Infect Immun 60:5048–5056
    [Google Scholar]
  12. Reyrat J. M., Lanzavecchia S., Lupetti P. & 11 other authors; 1999; 3D imaging of the 58 kDa cell binding subunit of the Helicobacter pylori cytotoxin. J Mol Biol 290:459–470 [CrossRef]
    [Google Scholar]
  13. Sahu A., Pangburn M. K. 1993; Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol 30:679–684 [CrossRef]
    [Google Scholar]
  14. Sapajatura V., Ushio H., Wada A., Yahiro K., Okumura K., Ogawa H., Hirayama T., Ra C. 2002; VacA, a vacuolating cytotoxin of Helicobacter pylori , directly activates mast cells for migration and production of proinflammatory cytokines. J Immunol 168:2603–2607 [CrossRef]
    [Google Scholar]
  15. Sommi P., Ricci V., Romano M., Ivey K. J., Solcia E., Ventura U. 1997; H.pylori -induced cell vacuolation in vitro : inhibitory action of heparin. Gastroenterology 112 (Suppl. S):A294– A294 [CrossRef]
    [Google Scholar]
  16. Trust T. J., Courtice I. D., Khouri A. G., Crosa J. H., Schiewe M. H. 1981; Serum resistance and hemagglutination ability of marine vibrios pathogenic for fish. Infect Immun 34:702–707
    [Google Scholar]
  17. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R. J. 2001; Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784–789 [CrossRef]
    [Google Scholar]
  18. Utt M., Wadstrom T. 1997; Identification of heparan sulphate binding surface proteins of Helicobacter pylori : inhibition of heparan sulphate binding with sulphated carbohydrate polymers. J Med Microbiol 46:541–546 [CrossRef]
    [Google Scholar]
  19. Utt M., Danielsson B., Wadstrom T. 2001; Helicobacter pylori vacuolating cytotoxin binding to a putative cell surface receptor, heparan sulfate, studied by surface plasmon resonance. FEMS Immunol Med Microbiol 30:109–113 [CrossRef]
    [Google Scholar]
  20. Xiang Z., Censini S., Bayeli P. F., Telford J. L., Figura N., Rappuoli R., Covacci A. 1995; Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 63:94–98
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.05389-0
Loading
/content/journal/jmm/10.1099/jmm.0.05389-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error